HIV treatment switch study for people with undetectable virus
Treatments studied
Part of Infections clinical trials.
This study tests a new long-acting HIV medication taken by mouth that may allow you to switch from your current daily pill. It is for people who have had an undetectable HIV viral load for at least 6 months and are currently on a stable HIV treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been taking Biktarvy (B/F/TAF) for at least 6 months.
- Your HIV viral load has been undetectable (below 50 copies/mL) for at least 6 months.
- You have no known resistance to the study drug (GS-3242).
- Your CD4 count is 200 or higher.
- You are not pregnant and agree to use contraception if you could become pregnant.
- You have normal kidney function (creatinine clearance at least 60 mL/min).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
This trial tests a new injectable HIV treatment (GS-3242 plus lenacapavir) compared to the daily pill Biktarvy for people just starting HIV therapy. If you qualify, you would receive shots every few weeks instead of taking a daily pill.
This study tests a new combination of two drugs to see if they can reduce the 'hidden' HIV that stays in your body even when you're on regular HIV treatment. The goal is to work toward a cure, not just control.
This trial provides continued access to Biktarvy (B/F/TAF) for children and adolescents who completed a previous Gilead HIV study. It ensures they can keep taking the medication without interruption.
This study tests a new drug, GS-0415, for people with HIV. The study will see if this drug can help control the virus. Participants will continue taking their regular HIV medication.
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.